"Canagliflozin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
| Descriptor ID |
D000068896
|
| MeSH Number(s) |
D02.886.778.075 D03.383.903.075 D09.408.348.113
|
| Concept/Terms |
Canagliflozin- Canagliflozin
- Canagliflozin Hemihydrate
- Hemihydrate, Canagliflozin
Canagliflozin, Anhydrous- Canagliflozin, Anhydrous
- Anhydrous Canagliflozin
- 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973
|
Below are MeSH descriptors whose meaning is more general than "Canagliflozin".
Below are MeSH descriptors whose meaning is more specific than "Canagliflozin".
This graph shows the total number of publications written about "Canagliflozin" by people in this website by year, and whether "Canagliflozin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 7 | 6 | 13 |
| 2018 | 7 | 7 | 14 |
| 2019 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Canagliflozin" by people in Profiles.
-
Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: A potential COVID-19 treatment. Int Immunopharmacol. 2021 Jul; 96:107773.
-
Novel Trial Design: CHIEF-HF. Circ Heart Fail. 2021 03; 14(3):e007767.
-
Research digest: SGLT2 inhibition in kidney and liver disease. Lancet Diabetes Endocrinol. 2019 06; 7(6):427.
-
The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice. Drugs. 2019 May; 79(7):733-750.
-
Case of acute unilateral emphysematous pyelonephritis and bacteraemia on treatment with canagliflozin. Postgrad Med J. 2018 12; 94(1118):714-715.
-
Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs. J Assoc Physicians India. 2018 Dec; 66(12):46-49.
-
Pump, pipes, and filter: do SGLT2 inhibitors cover it all? Lancet. 2019 01 05; 393(10166):3-5.
-
Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med. 2018 09 01; 178(9):1190-1198.
-
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? Diabetes Obes Metab. 2018 12; 20(12):2711-2723.
-
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. J Cell Physiol. 2018 01; 234(1):223-230.